Kymera Therapeutics CBO Executes $121,230 Stock Sale as Company Posts Clinical and Partnership Milestones
Kymera Therapeutics Chief Business Officer Noah Goodman sold 1,347 shares on April 14, 2026, at $90.00 per share for a total of $121,230 under a Rule 10b5-1 trading plan. The transaction leaves Goodman with direct ownership of 50,195.438 shares. The company is trading at $86.14 after a 244% year-over-year gain, and InvestingPro notes KYMR appears o…